

Sun Pharmaceutical Industries Limited  
Sun House, Plot No. 201 B/1,  
Western Express Highway, Goregaon (E),  
Mumbai – 400 063, Maharashtra, INDIA.  
Tel.: (91-22) 4324 4324  
Fax: (91-22) 4324 4343  
Website: [www.sunpharma.com](http://www.sunpharma.com)  
Email: [secretarial@sunpharma.com](mailto:secretarial@sunpharma.com)  
CIN: L24230GJ1993PLC019050



28 March 2026

**National Stock Exchange of India Limited**  
Scrip Symbol: SUNPHARMA

**BSE Limited**  
Scrip Code: 524715

### **Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Updates on Fibromun and Nidlegly**

---

This is to inform that our partner, Philogen, has provided the following clinical updates on Fibromun and Nidlegly as part of their financial results.

#### **Fibromun – STS and Glioblastoma**

**The Phase II FLASH study in last-line soft tissue sarcoma enrolled 94 patients randomised 1:1 to receive either Fibromun + dacarbazine or dacarbazine alone. The study did not meet its primary endpoint for Progression Free Survival (PFS).** Pretreated soft tissue sarcoma remains a highly challenging disease with significant unmet medical need. The company remains committed to advancing innovative therapeutic approaches with the goal of improving outcomes for soft tissue sarcoma patients.

With regard to glioblastoma studies, **the Phase II GLIOSTAR clinical trial conducted in 163 second-line patients did not meet its primary endpoint.** Despite the high unmet medical need, this indication remains extremely challenging, as other drugs (VEGF blockers, antibody-drug conjugates, anti-PD1 antibodies) have also failed to demonstrate an improvement in patient survival. However, in GLIOSTAR, an improvement in survival was observed in the subgroup of patients with limited exposure to alkylating agents.

The Company remains committed to the execution of the GLIOSUN clinical trial, conducted in treatment-naïve glioblastoma patients (i.e., first-line) and therefore not previously exposed to alkylating agents. GLIOSUN has completed the dose escalation phase and is initiating the subsequent dose expansion phase.

The GLIOSTELLA study, conducted in late-line glioblastoma patients, has completed patient enrollment in the United States and is expected to report survival data in September 2026.

Following the results of the FIBROSARC study in first-line soft tissue sarcoma, which showed encouraging signals in terms of survival in patients with liposarcoma and other sarcoma types, a request for Parallel Scientific Advice with the FDA and EMA has been submitted to define the design of a new Phase III registrational study (FIBROSARC-2). The conclusion of the process is expected in the second quarter of 2026, after which the study is planned to start, with overall survival as the primary endpoint. The rationale for this program is further supported by the observation of complete remissions in patients treated with Fibromun in combination with doxorubicin.

#### **Nidlegly™ – biopharmaceutical product developed for the treatment of skin cancers**

**Sun Pharmaceutical Industries Limited**  
Sun House, Plot No. 201 B/1,  
Western Express Highway, Goregaon (E),  
Mumbai – 400 063, Maharashtra, INDIA.  
Tel.: (91-22) 4324 4324  
Fax: (91-22) 4324 4343  
Website: [www.sunpharma.com](http://www.sunpharma.com)  
Email: [secretarial@sunpharma.com](mailto:secretarial@sunpharma.com)  
CIN: L24230GJ1993PLC019050



Following the withdrawal in 2025 of the Marketing Authorization Application previously submitted to the EMA for the melanoma indication, the Company is working on the preparation of a new submission in Europe during the current year.

In the United States, a Phase III clinical trial in locally advanced melanoma is ongoing, and is currently also active in Spain, and Switzerland, with planned expansion to additional countries. In March 2026, a Type C meeting was held with the U.S. Food and Drug Administration (FDA), during which data from the European study were presented and alignment was reached on the regulatory pathway aimed at obtaining approval in melanoma in the United States, subject to the completion and positive outcome of the ongoing study.

Within the non-melanoma skin cancer (NMSC) program, the Phase II “Duncan” study has been completed in patients with basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC). The excellent results in BCC were presented at the European Society for Medical Oncology (ESMO) 2025 conference reporting complete pathological responses in 52.6% of patients. Full results from the BCC and cSCC cohort will be published in 2026.

The Phase II “Intrinsic” study is currently ongoing, with a target of 70 patients affected by various forms of NMSC; to date, 65 patients have been treated in Italy and France.

The very positive results observed in the “Duncan” and “Intrinsic” trials have provided a strong rationale for the initiation of three new registrational studies in these indications in Europe and the United States, in BCC and cSCC. The design of these studies has already been discussed with the relevant regulatory authorities, and the enrolment of the first patients is expected in the second quarter of 2026.

An additional Scientific Advice with the FDA has also been completed to define a fourth registrational study in first-line BCC, in which the performance of Nidlegly™ will be compared with Hedgehog pathway inhibitors (HHI); the start of the study is expected in mid-2026.

#### **Additional Notes**

1. Emphasis has been added by Sun and some sequencing changed from original.
2. The above is an extract from Philogen’s financial results release. Here is the link to entire Press Release  
[https://www.philogen.com/documentation/PR/20260327\\_Board\\_of\\_Directors\\_approves\\_the\\_draft\\_financial\\_statements\\_and\\_the\\_consolidated\\_financial\\_statements\\_december\\_31st\\_2025\\_Pri ce\\_sensitive.pdf](https://www.philogen.com/documentation/PR/20260327_Board_of_Directors_approves_the_draft_financial_statements_and_the_consolidated_financial_statements_december_31st_2025_Pri ce_sensitive.pdf)

For **Sun Pharmaceutical Industries Limited**

(Anoop Deshpande)  
**Company Secretary and Compliance Officer**  
ICSI Membership No.: A23983